|
|
|
| Expression of PD-L1 and its clinical significance in colorectal cancer |
| DU Zhou1, HUANG Ping2, HUANG Guoyu3, HAN Shaoliang3, ZUO Zhigui4. |
| 1.Department of Hernia and Abdominal Wall Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 2.Office of Development and Planning, Wenzhou Medical University, Wenzhou 325035, China; 3.Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 4.Department of Colorectal Anal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China |
|
| Cite this article: |
|
DU Zhou,HUANG Ping,HUANG Guoyu, et al. Expression of PD-L1 and its clinical significance in colorectal cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2020, 50(1): 41-44.
|
|
|
|
Abstract Objective: To investigate the expression of PD-L1 in colorectal cancer and its relationship with clinicopathologic features, and meanwhile to discuss the clinical significance of PD-L1 expression. Methods:Colorectal cancer tissues and adjacent normal tissues were obtained from 50 patients with colorectal cancer. RTPCR and Western blot were conducted to detect the expression of PD-L1 in mRNA and protein levels. Results:The expression of PD-L1 in colorectal cancer tissues was elevated, compared with that in adjacent normal tissues (P<0.05). The elevated expression of PD-L1 in colorectal cancer tissues was correlated with cancer differentiation degree and lymphatic metastasis (P<0.05). Conclusion: PD-L1 was highly expressed in colorectal cancer patients, which was correlated with the clinicopathologic features.
|
|
Received: 07 May 2019
|
| |
|
|
|
[1] 许剑民, 钟芸诗. 多学科治疗团队在管理和治疗结直肠癌肝转移患者中的作用[J]. 中华胃肠外科杂志, 2010, 13(8): 565-568.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] WANG Q, HUANG Z, NI S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer[J]. PLoS One, 2012, 7(9): e44398.
[4] FERRONE S, WHITESIDE T L.Tumor microenvironment and immune escape[J]. Surg Oncol Clin N Am, 2007, 16(4): 755-774.
[5] FAGARASAN S, HOILJO T. T-indepent immune response: New aspects of B cell biology[J]. Science, 2001, 290(8): 89-92.
[6] MALASPINA T S, GASPAROTO T H, COSTA M R, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma[J]. Cancer Immunol Immunother, 2011, 60(7): 965-974.
[7] SASIDHARAN NAIR V, TOOR S M, TAHA R Z, et al. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer[J]. Clin Epigenetics, 2018, 10(1): 104.
[8] 赵晓敏, 李云涛, 季国忠. 结直肠癌筛查现状与进展[J]. 中国临床研究, 2016, 29(6): 838-841.
[9] SISIK A, KAYA M, BAS G, et al. CEA and CA19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4289-4294.
[10] HOSHINO N, HASEGAWA S, HIDA K, et al. Nomogram for predicting recurrence in stage II colorectal cancer[J]. Acta Oncol, 2016, 55(12): 1414-1417.
[11] SWAIKA A, HAMMOND W A, JOSEPH R W. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J]. Mol Immunol, 2015, 67(2 PtA): 4-17.
[12] 吴圣, 邵婧怡, 王芳, 等. PD-L1和PD-1在胃癌组织中的表达及其临床意义[J]. 安徽医科大学学报, 2015, 50(6): 821-825.
[13] HUA D, SUN J, MAO Y, et al. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carci-noma[J]. World J Gastroenterol, 2012, 18(9): 971-978.
[14] MUENST S, SOYSAL S D, GAO F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer[J]. Breast Cancer Res Treat, 2013, 139(3): 667-676.
[15] KANG M J, KIM K M, BAE J S, et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma[J]. Transl Oncol, 2013, 6(3): 282-289.
[16] ZHANG Y, HUANG S, GONG D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer[J]. Cell Mol Immunol, 2010, 7(5): 389-395.
[17] ARMAND P, NAGLER A, WELLER E A, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial[J]. J Clin Oncol, 2013, 31(33): 4199-4206.
[18] ZITVOGEL L, KROEMER G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy[J]. Oncoimmunology, 2012, 1(8): 1223-1225.
[19] LIN G, FAN X, ZHU W, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer[J]. Oncotarget, 2017, 8(48): 83986-83994.
[20] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16: 275-287.
[21] 张占芳, 张秋堂, 邢海洲, 等. PD-L1在急性白血病中的表达及其临床意义[J]. 中国实验血液学杂志, 2015, 23(4): 930-934.
[22] WANG L, MA Q, CHEN X, et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma[J].World J Surg, 2010, 34(5): 1059-1065.
[23] BOUSSIOTIS V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016, 375(18): 1767-1778. |
|
|
|
